PhenoNet, Inc. Completes Recruitment and Randomization in Phase IIb Clinical Trial Evaluating PHENOGENE-1A for Amyotrophic Lateral Sclerosis (ALS)
Today, PhenoNet, Inc., an advanced clinical-stage biotechnology company developing therapies for neurodegenerative diseases, announced the completion of recruitment and randomization on August 27, 2026, in its Phase IIb clinical trial evaluating PHENOGENE-1A as an adjunctive therapy for patients with mild-to-moderate Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease. Completing enrollment marks a key milestone in the company’s clinical development program and advances the study toward topline data.
PhenoNet Cleared by FDA to Begin Phase 3 Trial of Inhaled PHENOGENE-1A in Early Alzheimer's Disease
Today, PhenoNet, Inc. announced that the U.S. Food and Drug Administration (FDA) has notified the company that it may proceed with a Phase 3 clinical trial of its lead candidate, PHENOGENE-1A, in patients with early Alzheimer's disease (AD), including both APOE4 and non-APOE4 gene carriers. The agency issued the "May Proceed" notification on August 10, 2026, activating the company's Investigational New Drug (IND) application.
